Discontinued — last reported Q4 '24
Over 2 years (FY 2021 to FY 2024), Non Cash Acquired In Process Research And Development shows a downward trend with a -100.0% CAGR.
Higher values indicate significant investment in future pipeline growth through acquisitions rather than internal development.
This represents the non-cash expense associated with the acquisition of in-process research and development assets. It r...
Common in biopharma companies that frequently acquire early-stage assets or spin-out entities.
operating_non_cash_acquired_in_process_research_and_development| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.56M | $19.56M | $19.56M | $19.56M | $21.94M | $21.94M | $21.94M | $21.94M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +12.2% | +0.0% | +0.0% | +0.0% | -100.0% | — | — | — | — |
| YoY Change | — | — | — | — | +12.2% | +12.2% | +12.2% | +12.2% | -100.0% | — | — | — | — |